WO2003025139A3 - Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof - Google Patents

Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof Download PDF

Info

Publication number
WO2003025139A3
WO2003025139A3 PCT/US2002/029571 US0229571W WO03025139A3 WO 2003025139 A3 WO2003025139 A3 WO 2003025139A3 US 0229571 W US0229571 W US 0229571W WO 03025139 A3 WO03025139 A3 WO 03025139A3
Authority
WO
WIPO (PCT)
Prior art keywords
cobalamin
analogs
nucleic acids
derivatives
mediated delivery
Prior art date
Application number
PCT/US2002/029571
Other languages
French (fr)
Other versions
WO2003025139A2 (en
Inventor
Douglas A Collins
Matthew Callstrom
Franklyn G Prendergast
Original Assignee
Mayo Foundation
Douglas A Collins
Matthew Callstrom
Franklyn G Prendergast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation, Douglas A Collins, Matthew Callstrom, Franklyn G Prendergast filed Critical Mayo Foundation
Priority to AU2002362312A priority Critical patent/AU2002362312A1/en
Publication of WO2003025139A2 publication Critical patent/WO2003025139A2/en
Publication of WO2003025139A3 publication Critical patent/WO2003025139A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Abstract

This invention is in the area of cobalamin-mediated delivery of nucleic acids and analogs.
PCT/US2002/029571 2001-09-17 2002-09-17 Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof WO2003025139A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002362312A AU2002362312A1 (en) 2001-09-17 2002-09-17 Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32282101P 2001-09-17 2001-09-17
US60/322,821 2001-09-17
US41062702P 2002-09-13 2002-09-13
US60/410,627 2002-09-13

Publications (2)

Publication Number Publication Date
WO2003025139A2 WO2003025139A2 (en) 2003-03-27
WO2003025139A3 true WO2003025139A3 (en) 2003-08-21

Family

ID=26983625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/029571 WO2003025139A2 (en) 2001-09-17 2002-09-17 Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof

Country Status (2)

Country Link
AU (1) AU2002362312A1 (en)
WO (1) WO2003025139A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9173950B2 (en) 2012-05-17 2015-11-03 Extend Biosciences, Inc. Vitamin D-ghrelin conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
JP2003531105A (en) 1999-10-15 2003-10-21 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ Cobalamin conjugates useful as contrast agents and therapeutics
WO2005007889A1 (en) * 2003-07-21 2005-01-27 Oncotherapy Science, Inc. Method for diagnosing colorectal cancers
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
ATE467688T1 (en) 2006-03-07 2010-05-15 Avi Biopharma Inc ANTIVIRAL ANTISENSE COMPOUND AND METHOD FOR TREATING ARENAVIRUS INFECTION
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
CN111050806A (en) 2017-06-02 2020-04-21 波涛生命科学有限公司 Oligonucleotide compositions and methods of use thereof
CN113383078A (en) * 2018-12-06 2021-09-10 波涛生命科学有限公司 Oligonucleotide compositions and methods thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065529A1 (en) * 1998-06-15 1999-12-23 Alza Corporation Nucleic acid-cobalamin complexes and their use in gene therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065529A1 (en) * 1998-06-15 1999-12-23 Alza Corporation Nucleic acid-cobalamin complexes and their use in gene therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE SCISEARCH [online] GUY ET AL.: "Evaluation of coupling of cobalamin to antisense oligonucleotides by thin-layer and reversed-phase liquid chromatography", XP002962764, accession no. STN Database accession no. 1998:196974 *
JOURNAL OF CHROMATOGRAPHY B, vol. 706, no. 1, 27 February 1998 (1998-02-27), pages 149 - 156 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9173950B2 (en) 2012-05-17 2015-11-03 Extend Biosciences, Inc. Vitamin D-ghrelin conjugates
US9289507B2 (en) 2012-05-17 2016-03-22 Extend Biosciences, Inc. Carriers for improved drug delivery
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates

Also Published As

Publication number Publication date
AU2002362312A1 (en) 2003-04-01
WO2003025139A2 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
AU2002336367A1 (en) Adamts13 genes and proteins and variants, and uses thereof
AU2002246925A1 (en) Therapeutic delivery balloon
AU2002364893A1 (en) Delivery of medicaments to the nail
AU2002336288A1 (en) Weed controller metabolism proteins, genes thereof and use of the same
WO2003025139A3 (en) Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
AU2002314181A1 (en) Novel endothelially expressed dnas and proteins, and their use
MXPA03008393A (en) Bicyclic guanidine derivatives and therapeutic uses thereof.
MXPA03006162A (en) Mikanolide derivatives, their preparation and therapeutic uses.
AU2002329034A1 (en) Nucleic acid constructs for the delivery of polynucleotides into dna-containing organelles,and uses thereof
AU2002330245A1 (en) Isolated polypeptides and compositions from the venom of p. transvaalicus and methods of use
AU2002252773A1 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
AU2002355975A1 (en) Plasmids from anaerocellum thermophilum and uses thereof
AU2002246095A1 (en) Substituted propane-1,3-diamine derivatives and the pharmaceutical use thereof
AU2001292326A1 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
PT1363885E (en) Substituted propane-1,3-diamine derivatives and the pharmaceutical use thereof
WO2002066513A3 (en) Human circulating lekti fragments hf7072, hf7638 and hf14448 and use thereof
EP1375663A4 (en) Novel protein, dna thereof and use of the same
WO2001019850A3 (en) Nrage nucleic acids and polypeptides and uses thereof
AU2002239056A1 (en) Novel protein, dna thereof and use of the same
AU2001262084A1 (en) Maurocalcine, analogues thereof and their therapeutical uses
AU2002304780A1 (en) Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof.
AU2003211722A1 (en) Novel proteins, dnas thereof and use of the same
AU2003220067A1 (en) Jade nucleic acids, proteins and uses thereof
AU2001100510A4 (en) The walkers friend

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP